Milestone Scientific Reports Independent Industry Coverage Following Successful FDA Marketing Clearance of the CompuFlo(TM) Epidural Instrument
LIVINGSTON, NJ -- (Marketwired) -- 07/26/17 -- Milestone Scientific Inc. (NYSE: MLSS), developer of painless and precise computerized drug delivery instruments, reported the following independent industry trade coverage following its recent FDA marketing clearance of the epidural instrument:
Publication: MobiHealthNews (Daily blog, 185,000 unique visitors/mo.)
Headline: Milestone Scientific's new FDA-cleared epidural instrument senses pressure
Publication: Medgadget (500,000 monthly page views)
Headline: CompuFlo Epidural Anesthesia System Measures Pressure at Needle's Tip, Cleared by FDA
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a medical device company that designs, patents and commercializes innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, successfully commercialize its medical devices, achieve expected revenues, and obtain incremental regulatory approvals and otherwise achieve future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Source: Milestone Scientific Inc.
Released July 26, 2017